Fresenius in license agreement with Sanofi-Aventis

06 Apr 2010 Evaluate

Fresenius Kabi Oncology Ltd has entered into a license and settlement agreement with Sanofi-Aventis for injectable drug Eloxatin. The agreement resolves a patent infringement suit filed by Sanofi-Aventis in June 2007 in the US. Eloxatin is used for the treatment of stage-III colon cancer. The drug had net sales of $993 million in the US market in year 2009.

crackcrack
Peers
Company Name CMP
Sun Pharma Inds. 1652.10
Dr. Reddys Lab 1095.15
Cipla 1416.30
Lupin 1921.30
Zydus Lifesciences 844.60
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...